Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology

Shots: Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…

BySaurabh Chaubey4 days ago

NEWS

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Shots: Merck has signed a definitive agreement to acquire Cidara Therapeutics through a subsidiary, adding the company’s lead late-stage antiviral candidate CD388 to its pipeline Merck will acquire Cidara at $221.50 per share in cash, valuing the deal at approximately $9.2B. The transaction is expected to close in Q1’26 Cidara’s CD388 (currently in P-III) is…

ByRidhi RastogiNovember 17, 2025

NEWS

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Shots: Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65 Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure After…

BySaurabh ChaubeyNovember 8, 2025

INSIGHTS+

Know Your Investor: Samsara Biocapital (November’25 Edition)

Shots: Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such…

ByPrince GiriNovember 5, 2025

NEWS

QIAGEN to Acquire Parse Biosciences for ~$280M

Shots: QIAGEN signed a definitive agreement to acquire Parse Biosciences, expanding QIAGEN’s sample technologies portfolios and digital insights Under the agreement, QIAGEN will acquire Parse Biosciences for $225M upfront cash plus up to $55M in milestone payments. The deal is expected to close in December 2025, and Parse is projected to add $40M in sales…

ByDipanshu DixitNovember 5, 2025

VIEWPOINTS

Optimizing Life Sciences CRM: A Candid Conversation with Akshay Kapadia from Conexus Solutions

Shots: As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…

BySaurabh ChaubeyOctober 27, 2025

CXO TALKS

CXO Talks: Josh Wittner from Gene By Gene in a Riveting Conversation with PharmaShots

Shots: In this captivating episode of the CXO Talks Podcast, PharmaShots sits down with Josh Wittner, President, North America at Gene By Gene, to explore the company’s evolution and impact in the field of genetic testing Gene By Gene, a leading commercial genetic testing company, delivers cutting-edge genetic data services spanning a broad range of…

ByAditya SinghOctober 13, 2025

VIEWPOINTS

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots

Shots: Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape Leonard also highlights Mino-Lok, Citius’ innovative…

BySaurabh ChaubeyOctober 6, 2025

THOUGHTSPOT

The Rise of Industrial Metaverse: Smarter Pharma Starts at AUTOMA+ 2025

Digital transformation of the pharmaceutical industry is moving beyond buzzwords to real-world impact. At the Pharmaceutical Automation & Digitalisation Congress AUTOMA+ 2025 (24-25 November, Vösendorf, Austria), pharma leaders, including ZETA GmbH, Takeda and Sapio Sciences, are going to showcase how cutting-edge technologies, from digital twins and predictive analytics to minimal code platforms and AI-driven process…

BySaurabh ChaubeySeptember 23, 2025

INSIGHTS+

Know Your Investor: Cormorant Asset Management (September’25 Edition)

Shots: Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…

ByPrince GiriSeptember 4, 2025

Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Know Your Investor: Samsara Biocapital (November’25 Edition)

QIAGEN to Acquire Parse Biosciences for ~$280M

Optimizing Life Sciences CRM: A Candid Conversation with Akshay Kapadia from Conexus Solutions

CXO Talks: Josh Wittner from Gene By Gene in a Riveting Conversation with PharmaShots

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots

The Rise of Industrial Metaverse: Smarter Pharma Starts at AUTOMA+ 2025

Know Your Investor: Cormorant Asset Management (September’25 Edition)

Contact US

OUR INFORMATION

FOLLOW US